Infliximab use in Crohn's disease: impact on health care resources in the UK

Derek P Jewell, Jack Satsangi, Alan Lobo, Christopher Probert, Alastair Forbes, Subrata Ghosh, Jon Shaffer, Markus Frenz, Hazel Drummond, Gill Troy, Sue Turner, Lisa Younge, Lyn Evans, Mark Moosa, Barry Rodgers-Gray, Scot Buchan

Research output: Contribution to journalArticlepeer-review

55 Citations (Scopus)


To quantify the impact of infliximab therapy on health care resource utilization in the UK.
Original languageEnglish
Pages (from-to)1047-52
Number of pages6
JournalEuropean Journal of Gastroenterology & Hepatology
Issue number10
Publication statusPublished - Oct 2005


  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Cost-Benefit Analysis
  • Crohn Disease
  • Drug Costs
  • Epidemiologic Methods
  • Female
  • Great Britain
  • Health Care Costs
  • Health Resources
  • Health Services Research
  • Hospitalization
  • Humans
  • Male
  • Middle Aged
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha

Cite this